Document:

Exhibit
10.8

 

BINDING
HEADS OF AGREEMENT

PRIVATE AND CONFIDENTIAL

 

The
parties set out in Schedule 1 (together, the Vendors) are the holders of such majority of shares of Physimax as required to enforce
a sale of 100% of the issued share capital of Physimax Technologies Limited (an entity incorporated in Israel) (Physimax). Without
derogating from the above, Physimax will endeavor to solicit the signatures of all its shareholders on this Heads of Agreement prior
to Completion (the Selling Shareholders).

 

This
Heads of Agreement sets out the terms upon which Advanced Human Imaging Limited (ACN 602 111 115) of Suite 5, 71-73 South Perth Esplanade,
South Perth WA 6151 Australia (the Purchaser) agrees to acquire 100% of the issued Physimax Shares (as defined below), and the
Vendors agree to sell the Physimax Shares to the Purchaser.

 

Each
of the Purchaser and the Vendors are referred to as a Party and together the Parties

(as
the context requires).

 

This
Heads of Agreement is binding on the Parties and supersedes any and all previous correspondence, agreements or understandings between
the Parties.

 

	 	Term	Details
	 	 	 
	1.	Acquisition	Subject
        to the satisfaction (or waiver) of the Conditions (as defined in clause 5 below) and in consideration for the issue of the Consideration
        Securities (as that term is defined in clause 2) by the Purchaser to the Selling Shareholders, the Purchaser agrees to purchase,
        and the Vendors agree to sell, the Physimax Shares, free from any encumbrances and waiving any pre-emptive or call option rights
        associated with the Physimax Shares, on the terms and conditions pursuant to this Heads of Agreement (Acquisition).

    Title
    to and risk in the Physimax Shares shall pass to the Purchaser on completion of the Acquisition.

	 	 	 
	2.	Consideration	(a)            In
        consideration for the Acquisition, the Purchaser will issue the Selling Shareholders and the current holders of Physimax Options
        (or their nominees):

    (i)       AHI
    Shares at the Deemed Issue Price (Consideration Shares); and

    (ii)       AHI
    Options at the Deemed Conversion Price (Consideration Options),

    worth
    a total of $6,000,000 in aggregate (together, the Consideration Securities).

    (b)            The
    allocation of the Consideration Securities between the Selling Shareholders and the holders of the Physimax Options will be in accordance
    with an allocation list to be provided by Physimax as part of the due diligence.

    (c)            It
    is acknowledged and agreed that 50% of the Consideration Securities of each Vendor will be subject to six (6) months of voluntary
    escrow. The terms of the voluntary escrow will be set out in voluntary restriction deeds (Voluntary Restriction Deeds) in form and
    substance to be agreed upon before Completion.

 

    1

     

    

 

	 	Term	Details
	 	 	 
	3.	Shareholder approval	The
        issue of AHI ASX Shares and AHI Options that is contemplated in this Heads of Agreement is subject to and conditional on the
        Purchaser obtaining the required approvals from its shareholders at a General Meeting to issue AHI ASX Shares to the Selling
        Shareholders and the Consideration Options to the current holders of Physimax Options (Shareholder Approval).

    The
    Purchaser shall initiate the process of the Shareholder Approval (and its filing with the ASX) as soon as possible after execution
    of this Heads of Agreement.

	 	 	 
	4.	Waiver	By execution
    of this Heads of Agreement, the Vendors waive any pre-emptive rights or other rights which they may have over any Physimax Shares
    or Options to be transferred to the Purchaser under this Heads of Agreement, including (but not limited to) under any shareholders
    agreement, articles of association or call option or other legal right, effective from and subject to Completion
	 	 	 
	5.	Condition Precedent	Completion
        of the Acquisition is conditional upon the satisfaction (or waiver by the Parties) of the following conditions precedent, in
        addition to the satisfaction of the conditions for completion set forth in clause 8:

     

    (a)            the
    Purchaser obtaining all required third party, regulatory and governmental approvals and consents to give effect to the Acquisition,
    including any necessary shareholder approvals required by the Corporations Act or ASX Listing Rules (and any other applicable law
    or regulations);

     

    (b)            the
    Purchaser completing due diligence on Physimax to its satisfaction (in its sole and absolute discretion);

     

    (c)            Physimax
    and each of the parties that hold Physimax Option executing a deed in relation to the cancellation of the Physimax Options upon issuance
    of the Consideration Options, with effect from Completion (Option Cancellation Deeds);

     

    (d)            the
    Purchaser adopting an Israeli appendix to its share option plan, allowing issuance of options under the capital gain track (through
    a trustee) under section 102 of the Israeli Tax Ordinance and ready for filing with the Israeli tax authority immediately following
    Completion (the "IL Plan");

     

    (e)            Physimax
    obtaining all required third party, regulatory and governmental approvals and consents to give effect to the Acquisition, including
    any necessary shareholder approvals and the consent of the Israeli Innovation Authority;

     

    (f)            the
    issuance of a ruling by the Israeli Taxing Authority, approving the deferral of taxes arising from the Acquisition; and

     

    (g)            Physimax
    completing due diligence on Purchaser (for the benefit of its shareholders) to its satisfaction (in its sole and absolute discretion,
    (together, the Conditions).

     

    2

     

    

	 	Term	Details
	 	 	 
	 	 	

    Conditions
    (a), (b) and (c) are for the benefit of the Purchaser and may only be waived by the Purchaser.

     

    Conditions
    (d) through (g) (inclusive)are for the benefit of the Vendors and may only be waived by the Controlling Shareholders (on behalf of
    the other Vendors).

     

    The
    Parties will use their respective best endeavours and agree to cooperate and provide each other with all reasonable assistance, and
    to execute such documents and take such actions as required to ensure that the Conditions are satisfied promptly after the date of
    this Heads of Agreement.

	 	 	 
	6.	Termination	If
                                 by June 30, 2021, the Conditions are not satisfied or waived (as set forth above), either Party may
                                 terminate the agreement constituted by this Heads of Agreement by notice in writing to the other and
                                 the Parties will be released from their obligations under this Heads of Agreement. In addition, this
                                 Heads of Agreement may be terminated by mutual written consent of the parties at any time before June
                                 30, 2021. In such events, this agreement will be at an end and the Parties will be released from their
                                 obligations under this agreement (other than in respect of any breaches that occur prior to termination).

    In
    the event this Heads of Agreement is in effect on May 21, 2021, then the mutual Due Diligence process will be considered as successfully
    completed and the Purchaser shall pay Physimax an amount of US$60,000 (Due Diligence Payment) within no later than ten (10)
    days thereafter. The Due Diligence Payment shall be in addition to the Consideration Securities.

     

    The
    Due Diligence Payment is fully refundable in the event that any of the warranties set out in Part 2 of Schedule 3 are misleading
    or incorrect in circumstances involving fraud or intentional or deliberate misleading or deceptive conduct on the part of a Controlling
    Shareholder.

	 	 	 
	7.	Key Contributors	(a)            Physimax
                                 must provide the Purchaser with a list of its key employees and consultants (Key Contributors).

     

    (b)            The
    Purchaser is to use reasonable endeavours to amend the employment and consultancy agreements of the Key Contributors as soon as practicable
    after Completion, under which the Key Contributors are to agree to serve a minimum term of two additional years from the date of
    Completion (AHI Agreements). The terms and conditions of the AHI Agreements to be offered to the Key Contributors, including
    the engagement term and performance criteria, shall be agreed upon between the management of Physimax and the Purchaser prior to
    and as a condition to Completion.

     

    (c)            Subject
    to (f) below, the Key Contributors (and/or future employees and consultant identified as key contributors at the discretion of the
    founders of Physimax) will receive an aggregate of $2,000,000 worth of AHI Performance Rights at the same conversion price as the
    conversion price determined for the conversion of the ordinary shares of Physimax to Consideration Shares (Key Contributor Performance
    Rights) under the Purchaser’s Incentive Performance Rights Plan in proportions to be decided by Mr Ram Shalev, Physimax’s
    Chief Executive Officer at the date of this Heads of Agreement. The Purchaser shall work together with the management of Physimax
    in order to determine the appropriate mechanism for issuance of the Performance Rights (such as options / shares / RSUs) taking into
    account the tax benefits available to the Key Contributors. The AHI Performance Rights shall be for ADRs or AHI ASX, as shall be
    chosen by the Vendors for their Consideration Shares.

    3

     

    

	 	Term	Details
	 	 	

    (d)            The
    terms of the Key Employee Performance Rights, including any milestones, are to be set out in the AHI Agreements.

     

    (e)            If
    required, the Purchase must obtain ASX approval of the terms of the Key Employee Performance Rights prior to issuing them to the
    Key Contributors (which approval shall be obtained before Completion).

     

    (f)            The
    Purchaser shall initiate the process of the Shareholder Approval (and its filing with the ASX) as soon as possible after execution
    of this Heads of Agreement for the issue of the AHI Performance Rights.

     

    (g)            Subject
    to Physimax continuing to meet reasonable commercial objectives that are determined by the board of directors of the Purchaser (AHI
    Board) and the AHI Board determining that it continues to be the best interests of AHI’s shareholders to do so, the Purchaser
    shall fund the operation of Physimax as of Completion with a budget of US$60,000 per month. The budget shall be updated from time
    to time according to plan and needs as required to facilitate adequate resources to obtain the business goals agreed mutually by
    the Physimax management and the Purchaser.

	 	 	 
	8.	Completion	Completion
        of the Acquisition (Completion) will occur on the Completion Date at a time and place to be agreed by the Controlling
        Shareholders and the Purchaser. Without derogating from clause 3 above, at Completion:

     

    (a)            the
    Purchaser must issue the Consideration Shares to the Vendors in the proportions set out in the Formal Agreement;

    (b)            Physimax
    and the Vendors shall deliver, or cause to be delivered, to the Purchaser:

     

    (i)            share
    certificates in respect of 100% of the Physimax Shares;

    (ii)            the
    fully executed Option Cancellation Deeds;

     

    (iii)            separate
    instruments of transfer in registrable form for 100% of the Physimax Shares in favour of the Purchaser (as transferee) which have
    each been duly executed by or on behalf of the Vendors (as transferor);

    4

     

    

	 	Term	Details
	 	 	 
	 	 	

    (iv)            the
    list of the Key Contributors;

     

    (v)            the
    common seal (and any duplicate common seal, share seal or official seal) of Physimax (if any);

     

    (vi)            all
    available copies of the constituent documents of Physimax;

     

    (vii)           the
    minute books and other records of meetings or resolutions of shareholders and directors of Physimax (as available); and

     

    (viii)         all
    registers of Physimax (including the register of shareholders, register of directors, register of charges and all registers required
    by applicable laws) in proper order and condition and fully entered up to the Completion Date;

     

    (ix)            all
    cheque books, financial and accounting books and records, copies of tax returns and assessments, mortgages, leases, agreements, insurance
    policies, title documents, licences, indicia of title, contracts, passwords to computers, certificates and all other records, papers,
    books and documents of Physimax;

     

    (x)            every
    current permit, approval, authorisation, consent, exemption, filing, licence, notarisation, registration, password and waiver however
    described and any renewal or variation to any of them and all other documents issued to Physimax under any legislation, ordinance
    or otherwise relating to Physimax’s business activities;

     

    (xi)           all
    documents of right and/or title to the assets and undertakings of Physimax; and

     

    (xii)          the
    corporate records for Physimax, including all information relating to the assets and undertakings of Physimax and instruments of
    title for such assets and undertaking.

     

    (c)            The
    Vendors must procure that a meeting of the directors of Physimax is held to attend to the following matters (as applicable):

     

    (i)            the
    approval of the registration (subject to payment of duty) of the transfers of 100% of the Physimax Shares and the issue of a new
    appropriate certificates for the Physimax Shares in the name of the Purchaser;

     

    (ii)            recording
    the Purchaser as the holder of 100% of the Physimax Shares in Physimax’s registers of shareholders;

     

    (iii)            taking
    all other steps required under Physimax’s constituent documents and applicable laws to constitute and evidence the Purchaser
    as the sole holder of the Physimax Shares;

    5

     

    

	 	Term	Details
	 	 	 
	 	 	

    (iv)            the
    reconstitution of the Physimax board of directors as directed by the Purchaser; and

     

    (v)            such
    other business as may reasonably be required by the Purchaser to give effect to the Acquisition.

     

    The
    Parties’ obligations at Completion are interdependent and must take place simultaneously, as nearly as possible, unless otherwise
    agreed by the Purchaser and the Vendors, except that the Purchaser may, in its sole discretion, waive any or all of the actions that
    Physimax and/or the Vendors are required to perform under this clause 8.

     

    If
    a Party (Defaulting Party) fails to satisfy its obligations under clause 3 or this clause 8 on the day and at the place and
    time for Completion, then any other Party (Notifying Party) may give the Defaulting Party a notice requiring the Defaulting
    Party to satisfy those obligations within a period of 10 Business Days from the date of the notice and declaring time to be of the
    essence. The Parties agree, however, that none of Physimax or the Vendors can be a Notifying Party, in the event that one or more
    of them is a Defaulting Party; and that the Purchaser cannot be a Notifying Party, in the event that it is a Defaulting Party.

     

    If
    the Defaulting Party fails to satisfy those obligations within those 10 Business Days the Notifying Party may, without limitation
    to any other rights it may have, terminate this Heads of Agreement by giving written notice to the Defaulting Party.

	 	 	 
	9.	Warranties	(a)            Vendor
                                 Warranties

     

    By
    execution of this Heads of Agreement, each Vendor makes the representations and warranties set out in Part 1 of Schedule 3 at the
    date of this Heads of Agreement and on the Completion Date, subject to adjustments to be disclosed by the Vendor to the Purchaser
    in writing after the date hereof and on or before Completion (if any). In the event the Purchaser believes such adjustment to have
    a material adverse effect, the Purchaser may decide that Condition 5(b) above is not completed.

     

    (b)            Physimax
    Warranties

     

    By
    execution of this Heads of Agreement, each Controlling Shareholder makes the representations and warranties set out in Part 2 of
    Schedule 3 at the date of this Heads of Agreement and on the Completion Date, subject to any adjustment to be disclosed by the Controlling
    Shareholders to the Purchaser in writing after the date hereof and on or before Completion. In the event the Purchaser believes such
    adjustment to have a material adverse effect, the Purchaser may decide that Condition 5(b)

    above
    is not completed.

    6

     

    

	 	Term	Details
	 	 	 
	 	 	(c)
        Purchaser Warranties

     

    By
    execution of this Heads of Agreement, the Purchaser makes the representations and warranties set out in Schedule 4 at the date of
    this Heads of Agreement and on the Completion Date, subject to any adjustment to be disclosed by the Controlling Shareholders to
    the Purchaser in writing after the date hereof and on or before Completion. In the event the Controlling Shareholders believe such
    adjustment to have a material adverse effect, the Controlling Shareholders may decide that Condition 5(g) above

    is
    not completed.

	 	 	 
	10.	Indemnities	The
        following provisions shall become effective as of and subject to Completion:

     

    (a)            Each
    Vendor:

     

    (i)            is
    severally liable for a breach of the representations and warranties set out in Part 1 of Schedule 3 in relation to itself only; and

     

    (ii)            indemnifies
    and must hold the Purchaser harmless against all direct loss, damage and costs suffered by the Purchaser by reason of the warranties
    or representations set out in Part 1 of Schedule 3 proving to be false, misleading or incorrect in relation to itself only.

     

    (b)            The
    Controlling Shareholders jointly and severally indemnify and must hold the Purchaser harmless against all direct loss, damage and
    costs suffered by the Purchaser by reason of the warranties or representations set out in Part 2 of Schedule 3 proving to be false,
    misleading or incorrect. In the event the Purchaser chooses to file a Claim under Part 2 of Schedule 3, it must file it against both
    the Controlling Shareholders.

     

    (c)            The
    Purchaser indemnifies and keeps indemnified the Vendors against all loss, damage and costs suffered by Physmiax or the Vendors by
    reason of the warranties or representations set out in Schedule 4 proving to be false, misleading or incorrect.

	 	 	 
	11.	Limitations on liability	(a)            The
        maximum aggregate amount that a Vendor is required to pay in respect of a claim that is made under or in respect of Part 1 of
        Schedule 3 of this Heads of Agreement is limited to the value of the Consideration Shares that it receives on Completion.

     

    (b)            The
    maximum aggregate amount that a Controlling Shareholder is required to pay in respect of a claim that is made under or in respect
    of

     

    (i)            the
    warranties set out in paragraphs (a), (b), (c), (d), (m), (n), (p), (q), (r) and (s) of Part 2 of Schedule 3 of this Heads of Agreement
    is limited to 100% (Fundamental Warranties); and

    7

     

    

	 	Term	Details
	 	 	 
	 	 	(ii)            all
        the other warranties set out in Part 2 of Schedule 3 of this Heads of Agreement is limited to 50%, of the value of the Consideration
        Shares that it receives on Completion. Notwithstanding the above, the Controlling Shareholders shall not be liable for claims,
        unless the aggregated amount exceeds 60,000USD.

     

    (c)            Notwithstanding
    any other provisions of this Heads of Agreement, no Party will be liable for a claim that is made in respect of the warranties set
    out in Schedule 3 (Claim) unless written notice of the Claim is given to the applicable Party on or prior to:

     

    (i)            for
    the Fundamental Warranties, 30 September 2022; and

     

    (ii)            for
    the other warranties that are set out in Schedule 3, the date that is 12 months from Completion.

     

    (d)            Where
    a Vendor (including, for the purpose of clauses

     

    (d)
    through (i) hereof, a Controlling Shareholder) is liable under a Claim:

     

    (i)            the
    Vendor may elect to settle the Claim by the cancellation of the Consideration Shares held by it equal in value the liability amount
    in accordance with clause 11(f); and

    (ii)            where
    any of the Consideration Shares issued to the Vendor have been sold or transferred, the Vendor is liable to settle the Claim in cash
    in cleared funds to the Purchaser up to the amount of the value of the Consideration Shares sold or transferred (pro rata based on
    the value of the Consideration Shares that it receives on Completion).

     

    (e)            If
    a Vendor elects to cancel Consideration Shares in accordance with clause 11(d)(i) above, then such cancellation shall be in full
    and final satisfaction of all liability that the Vendor has in relation to a Claim up to the value of the Consideration Shares cancelled.
    In the event the Consideration Shares issued to a Vendor are insufficient to cover the damage, no additional compensation shall be
    payable by the Vendor (subject to (d)(ii) above).

     

    (f)            For
    the purposes of clause 11(d)(i):

     

    (i)            the
    number of Consideration Shares that must be cancelled or relinquished will be determined by the following formula:

     

    A
    = B ÷ C

     

    where:

    8

     

    

	 	Term	Details
	 	 	 

     

     

     

     

     

     

     

     

     

     

     

     

    

    (g)

     

    

     

     

    (h)

     

     

     

    (i)
	A=
                           The number of Consideration Shares that a Vendor must cancel or relinquish;

     

    B=
    The total liability of the Vendor in respect of the relevant Claim (as agreed or adjudicated by a court of competent jurisdiction);
    and

    C=
    the higher of the market value of the Consideration Shares as quoted on the ASX or NASDAQ (as applicable) (a) at the date of issuance
    of the Consideration Shares issued to the Vendors, and (b) at the time the relevant Claim is payable;

     

    (ii)           the
    Vendor by this clause grants the Purchaser a power of attorney to do all things necessary including to execute any document to give
    effect to the cancellation or relinquishment of the Consideration Shares on the Vendor’s behalf (to the extent the Vendor elects
    to satisfy the claim by cancellation or relinquishment of shares); and

     

    where
    more than one of the Vendors are liable as a result of a Claim, all of the Vendors so liable shall participate in satisfaction of
    such Claim pro rata to their portion of the Consideration Shares (as determined upon issuance).

     

    The
    limitations in this clause 11 do not apply to any Claim for loss or damage arising from an act of fraud or intentional or deliberate
    misleading or deceptive conduct on behalf of the Vendor or Controlling Shareholders (as applicable).

    The
    indemnity provisions set forth herein are the exclusive remedy available in connection with a breach of warranties under this Heads
    of Agreement.

     

	12.	Maintaining Status
    Quo	Up
    until the Completion Date or termination of this Heads of Agreement in accordance with its terms, the Controlling Shareholders shall
    procure that Physimax does not do any of the following without the prior written consent of the Purchaser (other than as contemplated
    in this Heads of Agreement):
	 	 	 
	 	 	(a)           enter
    into any material contract or incur any material liability or commitment to any material expenditure, unless specifically approved
    in writing by the Purchaser’s CEO;
	 	 	(b)           sell,
    assign or dispose of any legal or beneficial interest in Physimax’s business, intellectual property or other material assets;
	 	 	(c)           declare
    any dividends;
	 	 	(d)           vary
    its capital structure;
	 	 	(e)           vary,
    terminate or fail to renew any of its contracts, authorisations or commitments, except in the ordinary course of business;
	 	 	(f)            issue,
    or agree to issue, any equity or debt securities or hybrid securities, or grant or agree to grant any rights

    9

     

    

	 	Term	Details
	 	 	 

     

    (g)

     

    (h)

     

     

    (i)
	over
                           existing issued capital, or rights to be issued securities in the capital of Physimax;

    alter
    or agree to alter its constituent documents;

     

    create
    or permit the creation of any encumbrance over any of the assets or undertaking of Physimax; and

     

    enter
    into a buy-back agreement or resolve to approve the terms of a buy-back agreement.

	 	 	 	 
	13.	Formal
    Agreement	Notwithstanding
    the fact that this Heads of Agreement is legally binding on the Parties, the Parties agree to enter into a formal share sale agreement
    and any other agreement reasonably necessary to more fully document the terms of the Acquisition (to be prepared by the Purchaser’s
    solicitors) which shall be on terms acceptable to the Parties (acting reasonably) and which shall be consistent with the terms set
    out in this Heads of Agreement (Formal Agreement).
	 	 	 
	14.	Confidentiality
    and announcements	(a)	This
                                 Heads of Agreement and all other information disclosed by the Parties to each other (Confidential
                                 Information) is confidential and each Party shall ensure that the Confidential Information remains
                                 confidential and shall not be disclosed to any third party, save as required by applicable law or regulations.
                                 For the avoidance of doubt, the Vendors is required to comply with the continuous disclosure provisions
                                 of the ASX Listing Rules and subject to clause 14(b) will make such ASX announcements as is reasonably
                                 necessary in order to comply with the ASX Listing Rules.

	 	 	 	 
	 	 	(b)	Subject
    to compliance with its continuous disclosure obligations, the Vendors must use reasonable endeavours to consult with Physimax and
    the Purchaser on the form and content of any announcement to ASX of a matter contemplated by this Heads of Agreement before the announcement
    is made to ASX.
	 	 	 	 
	15.	Further
    Assurance	Each
    Party shall sign and execute and do all deeds, acts, documents and things as may reasonably be required by the other Parties to effectively
    carry out and give effect to the terms and intentions of this Heads of Agreement.
	 	 	 
	16.	Governing Law	The
    agreement constituted by this Heads of Agreement shall be governed by and construed in accordance with the law from time to time
    in Israel. The Parties agree to submit to the non-exclusive jurisdiction of the Courts of Tel Aviv – Jaffa, Israel and the
    Courts which hear appeals from those Courts.
	 	 	 
	17.	Assignment	None
    of the Parties may assign any of the rights or obligations conferred by this Heads of Agreement without the consent of the other
    Party.
	 	 	 
	18.	Costs	(a)	Each
    Party shall bear their own legal costs of and incidental to the preparation, negotiation and execution of this Heads of Agreement;
    it being agreed that the costs and expenses of the Vendors shall be covered by Physimax.

    10

     

    

	 	Term	Details
	 	 	 
	 	 	(b)            The
    Purchaser will pay any duty assessed on or in respect of this Heads of Agreement.
	 	 	 
	19.	Notices	Each
    notice authorised or required to be given to a Party shall be in writing and may be delivered personally or sent by properly addressed
    prepaid mail or email in each case addressed to the Party at its address or email address notified to the other from time to time.
	 	 	 
	20.	Remedies	The
    rights, power and remedies provided in this Heads of Agreement are cumulative with and not exclusive to the rights, power or remedies
    provided by law independently of this Heads of Agreement.
	 	 	 
	21.	Entire
    Agreement	This
    Heads of Agreement shall constitute the sole understanding of the Parties with respect to the subject matter and replaces all other
    agreements with respect thereto.
	 	 	 
	22.	Variation	No
                                 modification or alteration of the terms of this Heads of Agreement shall be binding unless made in writing
                                 dated subsequent to the date of this Heads of Agreement and duly executed by the Purchaser, the Controlling
                                 Shareholders and the Vendors holding a majority of the issued capital of the Company.

     

    The
    Vendors hereby irrevocably nominate the Controlling Shareholders as their representatives and constitute them as their proxy with
    a power of attorney to execute any document, waiver and consent required to give effect to this Agreement.

     

	23.	Severance	If any
    provision of this Heads of Agreement is invalid and not enforceable in accordance with its terms, all other provisions, which are
    self-sustaining and capable of separate enforcement without regard to the invalid provision, shall be and continue to be valid and
    forceful in accordance with their terms.
	 	 	 
	24.	Counterparts	This
    Heads of Agreement may be executed in any number of counterparts, each of which when executed and delivered to the other Parties
    shall constitute an original, but all counterparts together shall constitute one and the same agreement.
	 	 	 
	25.	Definitions	In
        this Heads of Agreement:

     

    (a)            Acquisition
    means the acquisition by the Purchaser of 100% of the Physimax Shares.

    (b)            ADR
    mean an American Depositary Receipt representing an interest in fully paid ordinary shares in the in the Purchaser (based on
    the ratio used under the IPO).

    (c)            AHI
    Share means:

    (i)            if
    the NASDAQ Listing has occurred prior to the relevant issue date, an ADR (or, at the election of the Vendors, an AHI ASX Share);
    and

    (ii)            if
    the NASDAQ Listing has not occurred prior to the relevant issue date, an AHI ASX Share.

    11

     

    

	 	Term	Details
	 	 	 
	 	 	(d)            AHI
        Option means the right to acquire an unissued AHI Share.

     

    (e)            AHI
    Performance Right means a right to be issued or transferred an ASHI Share, subject to the terms of the Purchaser’s Incentive
    Performance Rights Plan.

     

    (f)            Applicable
    Law means the constitutions of the Vendors and Purchaser and all applicable laws and regulations in any jurisdiction.

     

    (g)            ASX
    means ASX Limited (ACN 008 624 691) or the financial market operated by it as the context requires.

     

    (h)            ASX
    Listing Rules means the official listing rules of ASX.

     

    (i)            Controlling
    Shareholders means Ram Shalev and David Kahani.

     

    (j)            Conditions
    means the conditions precedents set out in clause 5.

     

    (k)            Completion
    Date means the day that is five business days after the last of the Conditions have been satisfied or waived in accordance with
    this Heads of Agreement.

     

    (l)            Corporations
    Act means the Corporations Act 2001 (Cth).

     

    (m)            Deemed
    Conversion Price means the Deemed Issue Price for the issue of a Consideration Share under clause 2(a)(i).

     

    (n)            Deemed
    Issue Price means:

     

    (i)            for
    AHI ASX Shares, the volume weighted average price of AHI ASX Shares for the five trading days prior to the relevant issue date; and

     

    (ii)            for
    ADRs, the issue price of the Purchaser’s ADRs under the IPO.

     

    (o)            Formal
    Agreement  has the meaning given in clause 13.

     

    (p)            IPO
    means the Purchaser’s initial public offering of ADRs on the NASDAQ.

     

    (q)            NASDAQ
    means the NASDAQ Stock Market.

     

    (r)            NASDAQ
    Listing means the Purchaser announcing that NASDAQ has provided confirmation to the Purchaser that it has approved the Purchaser’s
    application for admission to NASDAQ, subject only to conditions that the Purchaser reasonably believes it can satisfy.

     

    (s)            Physimax
    Share means the Physimax Ordinary Shares and the Physimax Preference Shares.

     

    (t)            Physimax
    Option means an option to acquire a Physimax Share.

     

    (u)            Physimax
    Ordinary Share means a fully paid ordinary share in the capital of Physimax.

    12

     

    

	 	Term	Details
	 	 	 
	 	 	(v)
    Physimax Preference  Share  means  a  Series  Pre-A Share in the capital  of
    the Company, of nominal value of NIS 0.01 each.
	 	 	 
	26.	Interpretation	Interpretation:

     

    (a)            a
    reference to the symbol "$" or to dollars in this Heads of Agreement are to US dollars;

     

    (b)            capitalised
    terms used in this Heads of Agreement have the definition ascribed above or otherwise in the terms of this Heads of Agreement;

     

    (c)            headings
    are for convenience only and do not affect its interpretation;

     

    (d)            an
    obligation or liability assumed by, or a right conferred on, 2 or more Parties or persons binds or benefits all of them jointly and
    each of them severally;

     

    (e)            the
    expression person includes an individual, the estate of an individual, a corporation, an authority, an association or joint venture
    (whether incorporated or unincorporated), a partnership and a trust;

     

    (f)            a
    reference to any Party includes that Party’s executors, administrators, successors and permitted assigns, including any person
    taking by way of novation;

     

    (g)            a
    reference to any document (including this Heads of Agreement) is to that document as varied, novated, ratified or replaced from time
    to time;

     

    (h)            a
    reference to any statute or to any statutory provision includes any statutory modification or re-enactment of it or any statutory
    provision substituted for it, and all ordinances, by-laws, regulations, rules and statutory instruments (however described) issued
    under it;

     

    (i)            words
    importing the singular include the plural (and vice versa) and words indicating a gender include every other gender;

     

    (j)            reference
    to Parties, clauses, Schedules or paragraphs are references to Parties, clauses, Schedules and paragraphs to or of this Heads Agreement
    and a reference to this Heads Agreement includes any Schedule to this Heads Agreement; and

     

    (k)            where
    a word or phrase is given a defined meaning, any other part of speech or grammatical form of that word or phrase has a corresponding
    meaning.

  

If
the terms and conditions set out above are acceptable, please execute this Heads of Agreement in the appropriate place below.

    13

     

    

 

SCHEDULE 1 – THE VENDORS

 

[SP
Comment: to be reviewed and completed by Physimax, please provide the full names of each of the Vendors]

 

	Vendor	 	Address	 	Number
    of

    Physimax 

    Ordinary 

    Shares held	 	 	Number
    of

    Physimax 

    Preference 

    Shares held	 	%
    of

    Consideration

    Securities
	Ram
    Shalev	 	[insert]	 	 	70,000	 	 	1,475
    (CLA 
conversion)	 	[insert]
	David Kahani	 	[insert]	 	 	20,000	 	 	-	 	[insert]
	LSY
    
International Inc.	 	[insert]	 	 	25,023	 	 	1,967	 	[insert]
	LionBird
    I L.P.	 	[insert]	 	 	41,111	 	 	2,460
    (CLA 
conversion)	 	[insert]
	Amichai &
    Yael Steimberg	 	[insert]	 	 	11,301	 	 	4,919	 	[insert]
	RealVest
    Profit Sharing Plan, Allan Goldberg, Trustee	 	[insert]	 	 	2,842	 	 	492	 	[insert]
	The successors
    of Uri Yogev	 	[insert]	 	 	2,500	 	 	-	 	[insert]
	Dr.Haim Blecher	 	[insert]	 	 	3,071	 	 	4,919	 	[insert]
	Edtom	 	[insert]	 	 	42,478	 	 	4,820+2,460
    (CLA 
conversion)	 	[insert]
	SPORTDOCS
    INVESTMENT LLC	 	[insert]	 	 	5,381	 	 	-	 	[insert]
	Physimax
    Investment LLC	 	[insert]	 	 	6,152	 	 	-	 	[insert]
	BAM Investors
    LLC	 	[insert]	 	 	4,732	 	 	-	 	[insert]
	SportGurus
    LLC	 	[insert]	 	 	5,915	 	 	2,951	 	[insert]
	Chaim Friedman
    (Trust) Ltd	 	[insert]	 	 	1,183	 	 	4,919	 	[insert]
	Rob Rubin	 	[insert]	 	 	3,904	 	 	9,838	 	[insert]
	Hunter Hamm
    (BTG)	 	[insert]	 	 	592	 	 	-	 	[insert]

    14

     

    

	Vendor	 	Address	 	Number
    of

    Physimax 

    Ordinary Shares

    held	 	 	Number
    of 

    Physimax 

    Preference 

    Shares held	 	%
    of

    Consideration

    Securities
	Pensco
    Trust for Ricardo Diaz (BTG)	 	[insert]	 	 	592	 	 	-	 	[insert]
	Jodies Zwerner
    Trust (BTG)	 	[insert]	 	 	592	 	 	-	 	[insert]
	Irina Meyer
    (BTG)	 	[insert]	 	 	710	 	 	-	 	[insert]
	Leo Loughead
    (BTG)	 	[insert]	 	 	592	 	 	-	 	[insert]
	[Altshuler
    Shacham ESOP in trust for exercised options (Gofer,Cohen)]	 	[insert]	 	 	3,176	 	 	-	 	[insert]
	Civana Kahani	 	 	 	 	 	 	 	2,459	 	 
	Itschak Friedman
    2012 Trust	 	 	 	 	 	 	 	4,919	 	 
	TOTAL	 	 	 	 	251,847	 	 	58,428	 	[insert]

    15

     

    

 

SCHEDULE 2 – PHYSIMAX’S
CAPITAL STRUCTURE

 

		(a)	Physimax
                                            Ordinary Shares: 251,847 fully paid ordinary shares, of nominal value of NIS 0.01 each

 

		(b)	Physimax
                                            Preference Shares: means 58,428 fully paid Series Pre-A Share, of nominal value of NIS
                                            0.01 each.

 

		(c)	Physimax
                                            Options:

 

The
Options schedule will be provided in the Formal Agreement.

 

		(i)	[insert]
                                            exercisable at $[insert] on or before [insert date]; and

 

		(ii)	[insert]
                                            exercisable at $[insert] on or before [insert date].

 

    16

     

    

 

SCHEDULE
3 – VENDOR AND PHYSIMAX REPRESENTATIONS AND WARRANTIES

  

Part
1 – Vendor Representations and Warranties

 

		(a)	Power
                                            and capacity

 

It
has full power and lawful authority to execute and deliver this document and to observe and perform or cause to be observed and performed
all of its obligations in and under this document.

 

		(b)	Incorporation

 

If
the Vendor is a company, it was validly incorporated, organised and subsisting in accordance with the laws of its place of incorporation.

 

		(c)	Authority

 

The
execution and delivery of this document has been duly and validly authorised by all necessary corporate action on behalf of the Vendor.

 

		(d)	No
                                            Trust

 

Unless
otherwise specified, it enters into and performs this Heads of Agreement on its own account and not as a trustee for or nominee of any
other person.

 

		(e)	Title

 

		(i)	It
                                            is the legal and beneficial owner of the Physimax Shares that are set out against its name
                                            in Schedule 1, which are free of all encumbrances and other third party interests or rights
                                            and comprise the total issued share capital of the Physimax.

 

		(ii)	Subject
                                            to the Required Approvals (as defined below), It is able to sell and transfer its shares
                                            in Physimax without the consent of any other person and free of any pre-emptive rights or
                                            rights of first refusal.

 

		(f)	No
                                            legal impediment

 

The
execution, delivery and performance of this document by the Vendor does not constitute a breach of any law or obligation or cause a default
under any agreement by which the Vendor is bound.

 

Part
2 – Controlling Shareholders Representations and Warranties

 

		(a)	Power
                                            and capacity

 

Subject
to obtaining the required approvals from its Board of Directors and the Vendors, and subject further to the Israeli Tax Authorities and
the Israeli Innovation Authority required approvals (the Required Approvals), Physimax has full power and lawful authority to
execute and deliver this document and to observe and perform or cause to be observed and performed all of its obligations in and under
this document.

 

		(b)	Incorporation

 

Physimax
is incorporated and validly existing in accordance with the laws of its place of incorporation.

 

    17

     

    

 

		(c)	Issued
                                            capital

 

		(i)	The
                                            capital structure of Physimax is set out in Schedule 2 and there are no equity securities,
                                            debt securities or hybrid securities on issue. Physimax has not issued securities with conversion
                                            rights to shares or securities in it and there are no agreements or arrangements under which
                                            options or convertible notes have been issued by it.

 

		(ii)	100%
                                            of the Physimax Ordinary Shares are fully paid and no money is owing in respect of them.

 

		(iii)	Subject
                                            to the Call Option Agreement (which may be exercised and which shall be terminated prior
                                            to Completion), no person has any right or option to subscribe for or otherwise to acquire
                                            any further shares in Physimax.

 

		(iv)	Physimax
                                            is not under any obligation to allot any shares to any person or persons, or otherwise to
                                            alter the structure of any part of its unissued share capital, and Physimax is not under
                                            any obligation to give any option over any part of their respective unissued share capital
                                            nor has Physimax offered to do any of the matters stated in this sub-paragraph.

 

		(d)	Subsidiaries

 

Aside
from Physimax Technologies, Inc., Physimax does not have any subsidiaries.

 

		(e)	Compliance
                                            with laws

 

To
the best of the Controlling Shareholders' knowledge and belief, neither Physimax nor any of their directors are in material breach of
any provision of any relevant laws, that might have adverse effect on the assets of Phyimax or on Completion of the transaction.

 

		(f)	No
                                            legal impediment

 

The
execution, delivery and performance of this document by Physimax does not constitute a breach of any law or obligation or cause a default
under any agreement by which Physimax is bound.

 

		(g)	No
                                            Event of insolvency

 

No
event of insolvency has occurred in relation to Physimax, or to the Controlling Shareholders' knowledge – the Vendors, nor, to
their knowledge, is there any act which has occurred, or any omission made which may result in an event of insolvency occurring in relation
to the Vendors or Physimax.

 

		(h)	No
                                            litigation or investigations

 

		(i)	Physimax
                                            and, to the Controlling Shareholders' knowledge, its directors are not involved in any litigation,
                                            arbitration or administrative proceeding relating to claims or amounts relating to Physimax
                                            nor is any such litigation, arbitration or administrative proceeding pending or threatened.

 

		(ii)	There
                                            is no litigation or proceeding pending or threatened against the Vendor which may defeat,
                                            impair, detrimentally affect or reduce the right, title and interest of Physimax in the assets
                                            described in Schedule 6 or of such Vendor in its Physimax Shares.

    18

     

    

		(iii)	To
                                            the Controlling Shareholders' knowledge, Physimax, its directors, and the Vendors are not
                                            the subject of any investigation by any regulatory body of any country nor is any such investigation
                                            pending or threatened, related to Physimax and the Physimax Shares.

 

		(iv)	To
                                            the Controlling Shareholders' knowledge, Physimax, its directors, and the Vendors are not
                                            the subject of any investigation or audit by the tax office of any country or state nor is
                                            any such investigation or audit pending or threatened.

 

		(i)	Consistency

 

The
terms of this Heads of Agreement are not inconsistent with and do not contravene the provisions of any other agreements or contract to
which Physimax, or to the Controlling Shareholders' knowledge – the Vendors, is a party.

 

		(j)	Material
                                            Contracts

 

Every
material contract, instrument or other commitment to which Physimax is a party is disclosed in Schedule 5, valid and binding according
to its terms and no party to any such commitment or contract is in material default under the terms of that commitment or contract.

 

		(k)	Corporate
                                            records

 

Physimax’s
statutory books (registers, minutes, resolutions) and returns (forms, lodgements) of that entity are up to date or are in the process
of being lodged (including without limitation, tax returns), and have been otherwise properly kept in accordance with all legal requirements
or practices.

 

		(l)	Assets

 

		(i)	All
                                            the material fixed assets, current assets and other assets and property owned by Physimax
                                            are:

 

		(A)	accurately
                                            described in full in Schedule 6;

 

		(B)	legally
                                            and beneficially owned by Physimax free of encumbrances (and, in particular, no such assets
                                            are the subject of any hire purchase agreement or credit purchase agreement or any agreement
                                            for payment of deferred terms); and

 

		(C)	not
                                            used by any person, other than Physimax.

 

		(ii)	Other
                                            than as disclosed in writing to Purchaser prior to the date of this Heads of Agreement, Physimax
                                            has no material operations, assets or agreements other than the assets described in Schedule
                                            6.

 

		(m)	Intellectual
                                            Property

 

		(i)	List
                                            in Part A of Schedule 6

 

Part
A of Schedule 6 accurately describes:

 

		(D)	all
                                            registered and unregistered business names and trade marks;

 

		(E)	all
                                            registered patents and designs;

    19

     

    

 

		(F)	all
                                            domain names; and

 

		(G)	all
                                            applications for registration of trademarks, domain names, patents and designs.

 

which
are owned or used at any time by Physimax in connection with its business (together the Intellectual Property Rights).

 

		(ii)	Right
                                            and title

 

Except
as set out Schedule 6, Physimax:

 

		(A)	owns
                                            all right, title and interest in and to the Intellectual Property Rights;

 

		(B)	has
                                            not licensed any of the Intellectual Property Rights, other than as presented in the Due
                                            Diligence in the ordinary course of business of Physimax granting use licence to its customers
                                            as part of its product; and

 

		(C)	has
                                            not assigned or disposed of any right, title or interest in the Intellectual Property Rights.

 

		(iii)	Legally
                                            and beneficially owned

 

The
Intellectual Property Rights are:

 

		(A)	in
                                            good standing in terms of any applicable legislation, regulations and other statutory requirements,
                                            and to the knowledge of Physimax, is not subject to any license, royalty obligation, assignment
                                            or disposal and as at the date of this Heads of Agreement and at Completion, no applications
                                            for patents or other types of intellectual property in respect of Physimax have been refused
                                            or are considered likely to be refused;

 

		(B)	legally
                                            and beneficially vested in Physimax;

 

		(C)	to
                                            the Controlling Shareholders' knowledge, not being presently infringed, nor are they the
                                            subject of any dispute, litigation or expungement application (whether threatened or otherwise);
                                            and

 

		(D)	not
                                            subject to any licence or authority in favour of any third party, and, to the Controlling
                                            Shareholders' knowledge, the exercise of them does not infringe the rights of any other parties.

 

		(iv)	Confidential
                                            Information

 

To
the Controlling Shareholders' knowledge, there has not been any misuse or unauthorised disclosure of any of Physimax’s confidential
information.

 

		(v)	Intellectual
                                            Property Licences

 

Part
B of Schedule 6 accurately describes all agreements under which Physimax obtains from any person the exclusive or non-exclusive right
to use, but not the ownership of, any of intellectual property rights (the Intellectual Property Licences) and each Intellectual
Property Licence is valid, binding and enforceable in accordance with its terms. To the Controlling Shareholders’ knowledge, Physimax
has complied at all times in all material terms with the terms of the Intellectual Property Licences, and no act or omission has occurred
which would entitle a licensor under an Intellectual Property Licence to terminate that licence.

 

    20

     

    

 

		(vi)	No
                                            use by other persons

 

The
Controlling Shareholders are not aware of any use by any other person of any Intellectual Property Rights, except under licenses given
by Physimax.

 

		(vii)	No
                                            infringement of other right

 

None
of the Intellectual Property Rights or other processes now or at any time employed, or the products now or at any time produced by Physimax,
constitutes or may constitute, to the Controlling Shareholders' knowledge, an unauthorised infringement of any intellectual property
rights of any other person.

 

	(n)	Liabilities

 

Physimax
does not have liabilities, contingent or otherwise, exceeding $50,000 in aggregate, other than certain convertible loan agreements between
Physimax and its current shareholders, which will be converted at Completion into Series Pre-A Shares of Physimax (the CLA’s) and
an outstanding liability to the IIA (incurred and payable on the ordinary course of business) and any salaries and recurrent expenses
incurred in the ordinary course of business.

 

		(o)	Licenses
                                            and approvals

 

To
the Controlling Shareholders’ knowledge, Physimax has all permits, licenses, authorities, registrations and approvals necessary
for properly carrying on its business and Physimax is not aware of any circumstance or fact which may result in the revocation, variation
or non-renewal in any material respect of any such permits, licenses, authorities, registrations and approvals.

 

		(p)	Claims

 

		(i)	At
                                            Completion, other than to the extent permitted by written consent from Purchaser, Physimax
                                            has no claim or obligations exists or will exist at Completion in relation to any existing,
                                            proposed or previous directors, managers, officers, employees, agents, consultants or contractors
                                            of Physimax.

 

		(ii)	Physimax
                                            has not failed to give any notice or to present any claim under any existing insurance policy.

 

		(q)	Accounts

 

The
accounts disclosed in Annexure A (Last Accounts)

 

		(i)	disclose
                                            a true and fair view of the state of the consolidated affairs, financial position and assets
                                            and liabilities of Physimax as at the balance date disclosed in the Last Accounts (Balance
                                            Date); For avoidance of doubt, the 2020FS are internal drafts only, subject to adjustments
                                            as be directed by Physimax accountants.

    21

     

    

 

		(ii)	includes
                                            all such reserves and provisions for tax as are adequate to cover all tax liabilities (whether
                                            or not assessed and whether actual, contingent, deferred or otherwise) of Physimax up to
                                            the Balance Date;

 

		(iii)	contain
                                            adequate provisions in respect of all other liabilities (whether actual, contingent, deferred
                                            or otherwise) of Physimax as at the Balance Date and proper disclosure (in note form) of
                                            any contingent or other liabilities not included or provided therein; and

 

		(iv)	were
                                            prepared:

 

		(A)	in
                                            accordance with the relevant accounting standards prescribed by the jurisdiction(s) in which
                                            it operates and were applied on a consistent basis and without making any revaluation of
                                            assets; and

 

		(B)	in
                                            the manner described in the notes to them.

 

Since
the Balance Date, Physimax’s business has been conducted in all material respects in the ordinary and usual course of business
other than for the Acquisition and:

 

		(i)	there
                                            has not been any material change in the nature, amount, valuation or basis of valuation of
                                            the assets or in the nature or amount of any liabilities of any shareholder of Physimax;

 

		(ii)	there
                                            has not arisen since the Balance Date any item, transaction or event of a material or unusual
                                            nature likely to have a material adverse effect on the operations or results or state of
                                            affairs of any shareholder of Physimax;

 

		(iii)	no
                                            amount has been acquired or disposed of, no liability has been incurred except in the ordinary
                                            course of business as disclosed in writing to the Purchaser, and no contingent liability
                                            has been incurred by any shareholder of Physimax;

 

		(iv)	none
                                            of the debts shown in the Last Accounts have been released or settled for an amount less
                                            than that reflected for such debts in the Last Accounts, and all such debts owing to and
                                            accounts receivable of the Purchaser are now and at Completion will be good and collectable
                                            in the amount disclosed in the Last Accounts (other than for any allowance in the Last Accounts
                                            in respect of doubtful debts). To the knowledge of Physimax, all such accounts receivable
                                            and debts are not and will not be subject to any counterclaim or set-off except for moneys
                                            payable by persons also shown as creditors of Target in the amounts shown in the Last Accounts
                                            (as such amounts may have been affected by transactions in the ordinary course of business
                                            since the Balance Date);

 

		(v)	all
                                            dividends declared by all shareholders s of Physimax have been properly and validly declared
                                            and no dividends have been declared by any shareholder of Physimax since the Balance Date;

 

		(vi)	To
                                            the knowledge of the Controlling Shareholder, no event of insolvency has occurred in respect
                                            of any shareholder of Physimax nor has any act occurred or any omission been made which may
                                            result in an event of insolvency occurring in respect of any shareholder of Physimax;

    22

     

    

		(vii)	no
                                            shareholder of Physimax has bought back any of its securities, has not converted its securities
                                            into a smaller or larger number nor entered into or resolved to approve a buy-back agreement;
                                            nor has any act occurred or any omission been made which may result in any of those events
                                            occurring in respect of any shareholder of Physimax; and

 

		(viii)	there
                                            has not been a change in the remuneration or benefits paid to or given or expected by any
                                            directors, managers, officers, consultants, contractors, agents or employees of any shareholder
                                            of Physimax except as stated in the DD process.

 

		(r)	Financings

 

There
are no:

 

		(i)	financing
                                            arrangements entered into by or on behalf of Physimax for the borrowing of money;

 

		(ii)	debentures,
                                            bonds, notes or similar debt instruments issued by any shareholder of Physimax;

 

		(iii)	guarantees
                                            given by any shareholder of Physimax, or to which any shareholder of Physimax is otherwise
                                            subject, in relation to any shareholder of Physimax or any other person;

 

		(iv)	encumbrances
                                            over the assets that are set out in Schedule 6; or

 

		(v)	except
                                            for the CLA’s and IIA grant, financing arrangements that restrict the disposal of Physimax.

 

		(s)	All
                                            material information

 

Any
information known to the Vendors or Physimax which might reasonably be regarded as material to a purchaser for value of the Physimax
Shares has been disclosed to the Purchaser prior to Completion and is true and accurate in all material respects.

    23

     

    

 

SCHEDULE 4 – PURCHASER REPRESENTATIONS
AND WARRANTIES

 

The
representations and warranties given by the Purchaser are as follows:

 

		(a)	Issue
                                            of the Consideration Shares

 

The
Purchaser has full power and authority and has obtained all third party consents necessary to allot and issue the Consideration Shares
to the Vendors in accordance with the Applicable Law.

 

		(b)	Ranking

 

The
Consideration Shares will be credited as fully paid and rank pari passu in all respects with all other Shares in the Purchaser on issue.

 

		(c)	Title
                                            to Consideration Shares

 

Upon
issue of the Consideration Shares, the Vendors will acquire full legal and beneficial title to the Consideration Shares, free and clear
of any encumbrance

 

		(d)	Trading

 

Unless
stated otherwise in the Heads of Agreement, the Consideration Shares, when issued at Completion, are registered for trading on the ASX
or NASDAQ, as applicable.

 

		(e)	Shareholder
                                            approval

 

Approval
from the Purchaser’s shareholders is not required to offer or issue the Consideration Shares.

 

		(f)	No
                                            legal impediment

 

The
execution, delivery and performance by the Purchaser of this Heads of Agreement complies with:

 

		(i)	each
                                            law, regulation, authorisation, ruling, judgement, order or decree of any government agency;

 

		(ii)	the
                                            constitution or other constituent documents of the Purchaser; and

 

		(iii)	any
                                            security interest or document.

 

		(g)	No
                                            litigation

 

Other
than as previously disclosed either publicly or specifically to the Vendors and / or Physimax, the Purchaser, its ultimate holding company
and / or its subsidiaries are not involved in any litigation, arbitration or administrative proceeding relating to claims or amounts
relating to the Purchaser, its ultimate holding company or its subsidiaries nor is any such litigation, arbitration or administrative
proceeding pending or threatened. There are no unsatisfied or outstanding judgments, orders, decrees, stipulations, investigations or
notices affecting the Purchaser or its subsidiaries or any person for whom the Purchaser or its subsidiaries may be vicariously liable.

    24

     

    

		(h)	No
                                            Event of insolvency

 

No
event of insolvency has occurred in relation to the Purchaser nor is there any act which has occurred or any omission made which may
result in an event of insolvency occurring in relation to the Purchaser.

 

		(i)	Binding
                                            obligations

 

This
agreement constitutes its legal, valid and binding obligations and is enforceable in accordance with its terms.

 

		(j)	Authorisations

 

The
Purchaser has taken all necessary action to authorise the execution, delivery and performance of this Heads of Agreement in accordance
with its terms.

 

		(k)	Continuous
                                            disclosure

 

The
Purchaser, its ultimate holding company and / or its subsidiaries has complied with all material disclosure requirements under Australian
law, including without limitation ASX Listing Rule 3.1 and is not withholding any information from the market under the carve outs set
out in ASX Listing Rule 3.1A.

    25

     

    

 

SCHEDULE 5 – CONTRACTS

 

To
be provided in the Formal Agreement.

 

    26

     

    

 

SCHEDULE 6 – PHYSIMAX ASSETS

 

To
be provided in the Formal Agreement in the following form.

 

Part
A – Intellectual Property Rights

 

		(a)	Business
                                            names and trademarks

 

(i)            [insert];
and (ii)

 

		(b)	Registered
                                            patents and designs

 

(i)            [insert];
and (ii)

 

		(c)	Domain
                                            names

 

(i)            [insert];
and (ii)

 

		(d)	Applications
                                            for registration of trademarks, domain names, patents and designs

 

(i)            [insert];
and (ii)

 

Part
B – Intellectual Property Licenses

 

		(a)	[insert];
                                            and

 

		(b)	[insert].

 

Part
C – Other Assets

 

		(a)	[insert];
                                            and

 

		(b)	[insert].

    27

     

    

 

Executed
by the Parties as an agreement

 

Dated
this 27th day of April 2021

 

	EXECUTED by ADVANCED HUMAN
    IMAGING LIMITED (ACN 602 111 115) in accordance with section 127 of the Corporations Act 2001 (Cth):	 	)

    )

    )

	 	 	 
		 	
	Signature of Chief Executive Office	 	Signature of company secretary
	 	 	 
	 	 	 
	Vlado Bosanac	 	Steven Richards
	Name of Chief Executive Office	 	Name of company secretary
	 	 	 
	EXECUTED by PHYSIMAX
    TECHNOLOGIES LIMITED in accordance with its constituent documents and place of incorporation:	 	)

    )

    )

    )

	 	 	 
		 	
	Signature of director	 	Signature of director/company
    secretary*
	 	 	 
	/s/
    Ram Shalev	 	/s/
    David Kahani
	Name of director	 	Name of director/company secretary*

  

    28

     

    

 [SP
Comment: if the Vendor is a company]

 

	EXECUTED
                           by [INSERT COMPANY NAME]

    in
    accordance with its constituent documents and place of incorporation:
	 	)

    )

    )

    )

     

	 	 	 
	Signature
    of director	 	Signatureofdirector/company
    secretary*
	 	 	 
	 	 	 
	 	 	 
	Name
    of director	 	Name
    of director/company secretary*

 

*please
delete as applicable

 

[SP
Comment: if the Vendor is an individual]

 

	SIGNED
                                            by [INSERT NAME OF INDIVIDUAL]

    in
    the presence of:
	 	)

    )

    )

	 	 	 
	Signature
    of witness	 	Signature
	 	 	 
	 	 	 
	 	 	 
	Name
    of witness	 	 

 

    29

     

    

 

ANNEXURE A – LAST ACCOUNTS

 

To
be provided in the Formal Agreement.

 

 

30Exhibit 10.21

 

 

 

10 December 2019

 

Prosser Enterprises Ltd ATF Prosser Family Trust 91 Hawkesbury
Crescent, Farrer,

ACT, 2607

 

Dear Nick,

 

LETTER OF VARIATION – OPPORTUNITY FOR EARLIER
CONVERSION

 

We refer to the converting note agreement which you (Investor)
executed with MyFiziq Limited (ACN 602 111 115) (Company) on or about 10th April 2018 (Agreement).

 

As you would be aware, the converting note which you hold
in accordance with the Agreement is currently due to mature on 31 December 2019 (Maturity Date).

 

This letter agreement is intended to vary your Agreement
to:

 

	(a)	extend the Maturity Date to 30 June 2020; and

 

	(b)	capitalise any interest owing to you as at the date of this letter agreement and any future interest payments due to you prior to
the Maturity Date.

 

Terms defined in the Agreement have the corresponding meaning
where used in this letter agreement (unless otherwise specified).

 

By this letter agreement, the Agreement is varied as follows:

 

Maturity Date: 30 June 2020.

 

Interest Payment Dates: Interest will accrue to the
Investor/s quarterly in arrears and the interest accrued to 31 December 2019 will be paid as follows:

 

i. $20,000 by 30 November 2019

 

 ii. The balance of approximately $38,630.14 by 31 January 2019

 

iii. Interest
will be paid on a monthly basis on the 1st of each calendar month at a rate of 8%pa being
$3,333p,

 

All interest accrued from 1 January 2020 shall be capitalised
(thereafter forming part of the Principal) and repaid on the Maturity Date.

 

Upon execution by all parties, this letter shall form a
binding deed varying the Agreement on the terms and conditions above.

 

     

     

    

 

To record your agreement to the above variation of the Agreement,
please execute this letter agreement where indicated below and return it to me.

 

For the avoidance of doubt, all remaining terms of the Agreement
remain unaltered other than as varied by this deed.

 

Yours sincerely

 

/s/ Steven Richards

Mr Steven Richards Company Secretary
MyFiziq Limited

 

    2

     

    

 

EXECUTED by the Parties as a deed.

 

	EXECUTED by MYFIZIQ LIMITED	)	 	 
	ACN 602 111 115	)	 	 
	in accordance with section 127 of the	)	 	 
	Corporations Act 2001 (Cth):	)	 	 

 

	 	 	 
	/s/ Vlado Bosanac	 	/s/ Steven Richards
	Signature of director	 	Signature company secretary
	 	 	 
	Vlado Bosanac	 	Steven Richards
	Name of director	 	Name of company secretary

 

	EXECUTED by Prosser Enterprises Ltd	)  ATF Prosser Family Trust)
	ACN [123 704 405]	)	 	 	 
	in accordance with section 127 of the	)	     	    
	Corporations Act 2001 (Cth):	 	 	 	 

 

	/s/ Nicholas Prosser	 	 
	Signature of sole director	 	Signature of director/company secretary*

 

	Nicholas Prosser	 	 
	Name of sole director	 	Name of director/company secretary*

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]